LONDON :A single dose of Pfizer's coronavirus vaccine may not generate a sufficient immune response to protect against dominant new variants, ...
WorldLONDON :A single dose of Pfizer's coronavirus vaccine may not generate a sufficient immune response to protect against dominant new variants, except in people who have already been infected with COVID-19, according to a UK study published on Friday.
FILE PHOTO: A medical worker prepares a dose of the"Comirnaty" Pfizer-BioNTech COVID-19 vaccine inside the exhibition palace transformed into a vaccination center in Nice as part of the coronavirus disease (COVID-19) vaccination campaign in France, April 29, 2021. REUTERS/Eric Gaillard
30 Apr 2021 11:31PMShare this contentBookmarkLONDON: A single dose of Pfizer's coronavirus vaccine may not generate a sufficient immune response to protect against dominant new variants, except in people who have already been infected with COVID-19, according to a UK study published on Friday (Apr 30). headtopics.com
The Imperial College-led study, which looked at immune responses among healthcare workers in Britain after their first dose of the Pfizer shot, found that those who had previously had mild or asymptomatic infection had enhanced protection against more infectious mutated variants that emerged in Britain and South Africa.
AdvertisementAdvertisementBut the immune response after a first dose of the shot was weaker in people who had not previously been infected, potentially leaving them at risk from such variants, researchers leading the work said."This study highlights the importance of getting second doses of the vaccine rolled out to protect the population," said Rosemary Boyton, a professor of immunology and respiratory medicine at Imperial who co-led the study.
"People who have had their first dose of vaccine and who have not previously been infected with SARS-CoV-2 are not fully protected against the circulating 'variants of concern'."The research, published in the journal Science, analysed blood samples for the presence and levels of immunity against the original strain of SARS-CoV-2 as well as the so-called UK variant, known as B117, and another known as B1351 that emerged in South Africa.
AdvertisementAdvertisementIt found that, after a first dose of the Pfizer vaccine, a boosted immune response in the shape of T-cells, B-cells and neutralising antibodies was associated with prior infection.In people who had not had COVID-19, however, a single vaccine dose produced lower levels of neutralising antibodies against the original virus and its mutant variants. headtopics.com
Death at River Valley High: Most students return to classes, counsellors deployed to school as support measure
3rd and 4th doses coming your way. Then 5th and 6th......... WHILE VIRYS MUTATES 所以那些還沒有完成接種第二針疫苗的國家是不能對印度，巴基斯坦，尼泊爾，斯里蘭卡開放的。
Most COVID-19 business capacity limits to end in New York region on May 19New York, New Jersey and Connecticut will lift most of their coronavirus capacity restrictions on businesses, including retail stores, food ...
19 people investigated for breaching COVID-19 measures at Fusionopolis pubSINGAPORE: Nineteen people are being investigated for suspected breaches of COVID-19 safe distancing measures at a pub located at Fusionopolis in ...
19 people investigated for breaching Covid-19 measures at Fusionopolis pub
Pfizer sees robust COVID-19 vaccine demand for years, US$26 billion in 2021 salesPfizer on Tuesday (May 4) raised its forecast for 2021 COVID-19 vaccine sales by more than 70 per cent to US$26 billion and said demand from ... 輝瑞疫苗賺大錢了！
South Korea says AstraZeneca, Pfizer COVID-19 vaccines 87% effective after first shotOne dose of COVID-19 vaccines from AstraZeneca Plc and Pfizer was 86.6% effective in preventing infections among people aged 60 and older, real world data released by South Korea showed on Wednesday. Data by the Korea Disease Control and Prevention Agency (KDCA) showed the Pfizer vaccine, jointly developed by BioNTech, was 89.7% effective in preventing infection at least two weeks after a first dose was given, while the AstraZeneca shot was 86.0% effective. Its analysis is based on more than 3.5 million people in South Korea aged 60 and older for two months from Feb. 26 and included 521,133 people who received a first dose of either Pfizer or AstraZeneca shot.